Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metabolic Regulation by Tumor Suppressor p53 in Li-Fraumeni Syndrome

NCT00406445 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT00406445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00406445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metabolic Regulation by Tumor Suppressor p53 in Li-Fraumeni Syndrome
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Observational
Overall status
Completed
Start date
January 23, 2007
Completion date
March 22, 2021
Enrollment
82 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carriers of p53 mutation, li-fraumeni syndrome, mitochondrial disorders